[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.184.210. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
February 4, 2004

Is C-Reactive Protein an Inflammation Opsonin That Signals Colon Cancer Risk?

Author Affiliations

Author Affiliations: Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Ill (Dr Pasche). Dr Pasche is a Contributing Editor, JAMA. Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (Dr Serhan).

JAMA. 2004;291(5):623-624. doi:10.1001/jama.291.5.623

Colorectal cancer is a leading cause of cancer-related morbidity and mortality in the Western world. A personal history of inflammatory bowel disease (IBD) is a well-established risk factor for colorectal cancer. Recent data suggest that the risk of colorectal cancer for individuals with IBD increases by 0.5% to 1.0% yearly, 8 to 10 years after diagnosis.1 The magnitude of colorectal cancer risk increases with early age at IBD diagnosis, longer duration of symptoms, and extent of the disease.1 In addition, a wealth of experimental, epidemiological, and randomized trial evidence suggests that long-term use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce the risk of colorectal adenoma and cancer.24 In both instances, the duration of either the inflammatory process or the use of anti-inflammatory agents is emerging as a key predictor of increased and decreased colorectal cancer risk, respectively.

First Page Preview View Large
First page PDF preview
First page PDF preview
×